Methotrexate-d3
Based on 1 Customer Validation
Methotrexate-d3 is the deuterated-labeled Methotrexate (HY-14519). Methotrexate (Amethopterin; CL14377; WR19039) is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.83%
- CAS No.: 432545-63-6
- Formule: C20H19D3N8O5
- Masse moléculaire:457.46
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Activité biologique
|
COX-2 |
IL-8 |
iNOS |
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 432545-63-6
-
Unlabeled CAS 59-05-2
-
Appearance Solid
-
Masse moléculaire 457.46
-
Formule C20H19D3N8O5
-
Color Light yellow to brown
-
SMILES
NC1=NC(N)=NC2=C1N=C(CN(C3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)C=C3)C([2H])([2H])[2H])C=N2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Pureté et documentation
-
Fiche technique (270 KB)
-
SDS (739 KB)
- English - EN (739 KB)
- Français - FR (739 KB)
- Deutsch - DE (739 KB)
- Norwegian - NO (739 KB)
- Español - ES (739 KB)
- Swedish - SV (739 KB)
- Italian - IT (739 KB)
- Korean - KR (739 KB)
- Portuguese - PT (739 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Cronstein BN, et al. The mechanism of action of methotrexate. Rheumatic diseases clinics of North America. 1997 Nov;23(4):739-55. [Content Brief]
[2]. Bedoui Y, et al. Methotrexate an Old Drug with New Tricks. International journal of molecular sciences. 2019 Oct 10;20(20):5023. [Content Brief]
[4]. Ohbayashi M, et al. Induction of pulmonary fibrosis by methotrexate treatment in mice lung in vivo and in vitro. The Journal of toxicological sciences. 2010 Oct;35(5):653-61. [Content Brief]
[5]. Yang M, et al. Acute treatment with methotrexate induces hippocampal dysfunction in a mouse model of breast cancer. Brain research bulletin. 2012 Oct 01;89(1-2):50-6. [Content Brief]
[6]. Banji D, et al. Evaluation of the concomitant use of methotrexate and curcumin on Freund's complete adjuvant-induced arthritis and hematological indices in rats. Indian J Pharmacol. 2011 Sep;43(5):546-50. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- Methotrexate-d3
- 432545-63-6
- Isotope-Labeled Compounds
- Antifolate
- Dihydrofolate reductase (DHFR)
- NO Synthase
- COX
- Interleukin Related
- tetrahydrofolate
- AICAR transformylase
- ROS
- COX-2
- iNOS
- HMGB1 alarmin
- purine/pyrimidine synthesis
- dihydrofolate reductase
- methotrexate-polyglutamates
- leukotriene B4
- Inhibitor
- inhibitor
- inhibit